

1 **Differential Tractography as a Track-Based Biomarker for Neuronal Injury**

2 **Authors:** Fang-Cheng Yeh^{1,2,*}, Islam M. Zaydan³, Valerie R. Suski³, David Lacomis^{3,4}, R. Mark
3 Richardson¹, Joseph C. Maroon¹, and Jessica Barrios-Martinez¹

4 **Affiliations:**

5 ¹Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh,
6 Pennsylvania, United States

7 ²Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, United States

8 ³Department of Neurology, and the ⁴Live Like Lou Center for ALS Research, University of Pittsburgh
9 School of Medicine, Pittsburgh, PA, United States

10 *Correspondence to:

11 Fang-Cheng Yeh, M.D. Ph.D.

12 Department of Neurological Surgery,

13 Department of Bioengineering,

14 University of Pittsburgh, Pittsburgh, Pennsylvania

15 Email: frank.yeh@pitt.edu

16

17 **One Sentence Summary:**

18 Differential tractography utilizes repeat diffusion MRI scans to identify the exact segment of tracks with a
19 neuronal injury.

20

21 **Abstract**

22 Diffusion MRI tractography has been used to map the axonal structure of human brain, but its ability to
23 detect neuronal injury is yet to be explored. Here we report differential tractography, a new type of
24 tractography that utilizes repeat MRI scans and a novel tracking strategy to map the exact segment of
25 fiber pathways with a neuronal injury. We examined differential tractography on multiple sclerosis,
26 Huntington disease, amyotrophic lateral sclerosis, and epileptic patients. The results showed that the
27 affected pathways shown by differential tractography matched well with the unique clinical symptoms of
28 the patients, and the false discovery rate of the findings could be estimated using a sham setting to
29 provide a reliability measurement. This novel approach enables a quantitative and objective method to
30 monitor neuronal injury in individuals, allowing for diagnostic and prognostic evaluation of brain
31 diseases.

32

33 **Keywords:** diffusion MRI, differential tractography, fiber tracking, imaging biomarker, neuronal injury,
34 multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis, epilepsy.

35 Introduction

36 Magnetic resonance imaging (MRI) is a commonly used neuroimaging technique for revealing a
37 structural change in patients with neurological disorders. Studies have used structural MRI to reveal
38 gray matter atrophy in patients with multiple sclerosis (Rovira et al., 2015; Wattjes et al., 2015) and
39 atrophy in the caudate in patients with Huntington disease (Tabrizi et al., 2009; Tabrizi et al., 2012). In
40 addition to structural MRI, diffusion MRI has also been explored as an imaging biomarker for early-stage
41 neuronal injury before atrophy happens. Animal studies have used diffusion tensor imaging
42 (DTI)(Basser et al., 1994) to detect acute demyelination or axonal loss (Song et al., 2002; Song et al.,
43 2005). The decrease of anisotropic diffusion has been shown to be correlated with axonal loss (Budde et
44 al., 2009; Huisman et al., 2004; Werring et al., 1999; Werring et al., 2000). However, anisotropy remains
45 a voxel-based measurement, which is prone to local variations such as partial volume effect (Henf et al.,
46 2018; Wang et al., 2011) or signal noise, thereby limiting its clinical applications (Melonakos et al., 2011).
47 Greater specificity and sensitivity could be achieved by aggregating voxel-wise anisotropy changes
48 along fiber pathways and grouping them into a “track”.

49

50 To this end, we propose a novel method called “differential tractography” to provide a track-based
51 biomarker for neuronal injury. This method compares repeat scans of the same individuals to capture
52 neuronal injury reflected by a decrease of anisotropic diffusion, or “anisotropy” (Fig 1a-1c). To achieve a
53 higher specificity, we imbued the deterministic fiber tracking algorithm (Yeh et al., 2013) with a novel
54 “*tracking-the-difference*” paradigm. This was realized by adding an additional criterion to track along
55 trajectories on which a decrease of anisotropy was found between repeat scans (Fig. 1d-1e). Integrating
56 this “tracking-the-difference” paradigm into the fiber tracking process resulted in a new tractography

57 modality that tracks the exact portion of pathways exhibiting substantial differences in anisotropy. The
58 additional criterion ignored unaffected regions and enhanced meaningful findings related to neuronal
59 injury. In comparison, the conventional fiber tracking (Wedeen et al., 2012) is based on a
60 “*tracking-the-existence*” paradigm. It only considers anisotropy from one MRI scan and thus will include
61 all existing pathways regardless of whether they have an injury.

62 To implement differential tractography, the algorithm requires one anisotropy value for each fiber
63 population to calculate its longitudinal change, but the fractional anisotropy (FA) derived from DTI is a
64 voxel-based measurement, and thus all fiber orientations within the same voxel will inherit the same
65 anisotropy value. To overcome this limitation, we used the anisotropic component of the spin distribution
66 function (SDF)(Yeh et al., 2010) as an anisotropy measurement for each fiber population. SDF could
67 provide one anisotropy measurement for each fiber population. This approach has been shown to be
68 more robust against partial volume effect (Yeh et al., 2013) and achieved high accuracy in a recent
69 competition study (ID#3)(Maier-Hein et al., 2017).

70 To further maximize the detection power, we used a diffusion MRI acquisition that sampled 22 diffusion
71 sensitizations (b-values) at 257 directions, a substantial improvement over one sensitization at 30~60
72 directions used in the conventional settings, or 3 diffusion sensitizations at 180 directions used in the
73 current mainstream studies (Glasser et al., 2016). The higher number of diffusion sensitizations greatly
74 increased the chance to detect neuronal injury that involves only a subtle change in the restricted
75 diffusion (Wang et al., 2011). We also introduce a novel sham setting that can estimate the false
76 discovery rate (FDR) of differential tractography to provide a reliability measurement against local
77 random error.

78

79 To evaluate the performance, we applied differential tractography to patients with four different clinical
80 scenarios at different stages of neuronal injury (demographic information listed in Table 1). The first
81 scenario was multiple sclerosis (MS) with the first episode of optic neuritis. The baseline scans were
82 acquired right after the onset of the visual symptom, and the follow-up diffusion MRI scans were
83 acquired 6 months after. This scenario tested differential tractography at the early stage of neuronal
84 injury to explore its sensitivity, and any meaningful findings should be located near the visual pathways.
85 The second scenario was the manifested Huntington disease (HD) with worsening clinical motor scores
86 during the interval of their repeat MRI scans. We examined whether differential tractography could
87 detect progressing neuronal injury at striatal pathways that are commonly affected by the disease. The
88 third scenario studied the neuronal injury in an amyotrophic lateral sclerosis (ALS) patient with a
89 deteriorating functional motor score. We examined whether differential tractography could be correlated
90 with the patient's clinical presentation. Last, we applied differential tractography to an epileptic patient
91 treated by anterior temporal lobectomy. The baseline scan was acquired before the surgery, and the
92 follow-up scan was acquired one year after the surgery. This examined whether differential tractography
93 could correctly locate pathways with established neuronal injury after surgery, and meaningful findings
94 should be in pathways previously connected to the area of resection. We also applied differential
95 tractography to a normal subject to demonstrate how differential tractography may capture false results.

96 **Material and Methods**

97 **MRI experiments on clinical patients with neurological disorders**

98 The diffusion MRI acquisition included a baseline scan and another follow-up scan (acquired months
99 later) of the same subject. We acquired scans on 6 patients with different neurological diseases

100 including MS, HD, ALS, and epilepsy, in addition to one healthy volunteer. Table 1 summarizes their
101 basic demographic and scan interval information, and brief medical history of these patients are
102 summarized in Supplementary Materials. The ALS patient was previously reported (Abhinav et al.,
103 2014). The diffusion data were acquired on a 3T Tim Trio System (Siemens, Erlangen, Germany) using
104 a pulsed-gradient spin-echo 2D echo-planar imaging sequence. A 32-channel coil was used with a head
105 stabilizer to limit head motion. Each diffusion MRI scan acquired 22 b-values ranging from 0 to 7,000
106 s/mm² at a total of 257 diffusion sampling direction using a q-space imaging scheme (Callaghan, 1991).
107 The in-plane resolution and slice thickness were 2.4 mm. TE=154 ms, and TR=9500 ms. The total
108 scanning time was 45 minutes.

109 This is a retrospective study, and the multi-band sequence was not available previously. Currently, the
110 same protocol using multi-band sequence has a much shorter scanning time of 12 minutes (see
111 Discussion section for details).

112 **Quality control of diffusion MRI data**

113 We applied a series of quality control to minimize possible false results due to acquisition issues. The
114 first quality control was done by checking whether the image dimension, resolution, and b-table were
115 consistent between repeat scans. All scan data were confirmed to have a consistent setting between
116 repeat scans.

117 The second quality control was done by calculating the mean Pearson correlation coefficient of the
118 “neighboring” diffusion-weighted images:

$$119 \quad \frac{1}{n} \sum_{i=1}^n \rho(S_i, S_{N(i)}) \quad (1)$$

120 where ρ calculates the Pearson correlation coefficient, S_i is the i -th diffusion weighted image, and $N(i)$
121 returns the index of the neighboring diffusion-weighted image acquired by the most similar diffusion
122 sensitization in the q-space:

$$123 \quad N(i) = \arg \min_{j, j \neq i} \left\| \sqrt{b(i)} \vec{g}(i) - \sqrt{b(j)} \vec{g}(j) \right\| \quad (2)$$

124 $b(i)$ is the b-value, and $\vec{g}(i)$ is the diffusion encoding direction. The resulting values in Eq. (1) ranges
125 between 0.6~0.8, and a data set would be rejected if the baseline and follow-up scans have a difference
126 in mean Pearson correlation coefficient greater than 0.1. In this study, one ALS patient's data we
127 recruited previously (Abhinav et al., 2014) was rejected because the baseline scan had a substantially
128 lower value due to slice shift during the scan.

129 The third quality control step was identifying slice-wise signal dropout for each slice in each
130 diffusion-weighted image. This examination excluded slices with a large background region greater than
131 15/16 of the entire slice area (defined by the brain mask). For each slice, we calculated its Pearson
132 correlation coefficients with four of its signal-related slices, including its upper and lower adjacent slices
133 and the same-location slices of two neighboring diffusion-weighted images defined by Eq. (2). The
134 maximum of these four correlation values was used as the representative correlation coefficient of the
135 slice, and a signal dropout would result in a decrease of this representative correlation coefficient. If a
136 slice had an average decrease of representative correlation coefficient greater than 0.1 in comparison
137 with its four related slices, we identified it as a signal dropout slice. In this study, we accepted the data
138 set if the number of signal dropout slices was smaller than 0.1% of the total slice number (i.e. < 25
139 slices). All data set were screened and passed this criterion.

140 The fourth quality control was checking the b-table orientation using the fiber coherence index (Schilling
141 et al., 2019). One scan was found to have slices order flipped upside down. The slice order and b-table

142 were corrected before further analysis. The above-mentioned quality control routines are available on
143 DSI Studio (<http://dsi-studio.labsolver.org>).

144 After the quality control steps, the diffusion data of the follow-up scans were compared with baseline
145 scans using the following analysis:

146 **Empirical distribution of water diffusion**

147 The empirical distribution of water diffusion was calculated from diffusion-weighted signals using
148 generalized q-sampling imaging (GQI)(Yeh et al., 2010). This “empirical distribution” has no assumption
149 of the underlying distribution (e.g. Gaussian distribution), and thus it can be applied to a variety of fiber
150 or biological conditions. The empirical distribution calculated from GQI, termed spin distribution function
151 (SDF), has a different physical definition from the *diffusivity* calculated from DTI that quantifies how fast
152 the diffusion is. SDF quantifies the accumulated spin density of restricted diffusion sampled at any
153 orientations, and it can be calculated using the formula:

$$154 \Psi_0(\mathbf{r}, \hat{u}) = Z_0 \sum_i W_0(\mathbf{r}, i) \operatorname{sinc} \left(\sigma \sqrt{6Db(i)} \langle \hat{g}(i), \hat{u} \rangle \right) \quad (3)$$

155 $\Psi_0(\mathbf{r}, \hat{u})$ is the SDF value oriented at \hat{u} and sampled from a voxel located at \mathbf{r} . Z_0 is a scaling constant
156 to convert the arbitrary unit of the diffusion signals to a density unit. i iterates through each diffusion
157 weighted signals $W(\mathbf{r}, i)$, and $b(i)$ is the b-value, $\hat{g}(i)$ is the direction of the diffusion sensitization
158 gradient. σ is the diffusion sampling ratio controlling the displacement range of the diffusing spins (1.25
159 was used in this study). D is the diffusivity of free water at room temperature.

160 We then calculated the SDFs of the follow-up scan and transformed them into the space of the baseline
161 scan (Fig. 1a and Fig. 1b) so that they could be directly compared. This was done using q-space

162 diffeomorphic reconstruction (QSDR)(Yeh and Tseng, 2011), a method that generalized GQI to accept
163 spatial transformation in the reconstruction. QSDR allowed us to simultaneously reconstruct and
164 transform SDF from the follow-up scan to the space of the baseline scan using the following formula:

$$165 \Psi_1(\mathbf{r}, \hat{u}) = Z_1 \sum_i W_1(\phi(\mathbf{r}), i) \text{sinc} \left(\sigma \sqrt{6Db(i)} \langle \hat{g}(i), \mathbf{J}(\mathbf{r}) \hat{u} \rangle \right) \quad (4)$$

166 where $\phi(\mathbf{r})$ transforms spatial coordinate \mathbf{r} from the space of the baseline scan to that of follow-up scan.
167 $W_1(\phi(\mathbf{r}), i)$ is the diffusion-weighted signals at coordinate $\phi(\mathbf{r})$. $\mathbf{J}(\mathbf{r})$ is the Jacobian matrix at the
168 same coordinate that rotates the unit vector \hat{u} . There other variables follow the same notations in Eq.
169 (3).

170 Since the scans were from the same subject, we assumed there was only “rigid body” transformation (i.e.
171 only rotation or translocation) between the scans, and the transformation was a simple matrix-vector
172 multiplication. Please note that this assumption could be violated if there was a large tissue distortion
173 due to edema or tissue removal, and a nonlinear spatial registration should be used in QSDR to handle
174 this problem. The rigid body transformation matrix was obtained by linear registering the b0 images (or
175 the sum of all diffusion-weighted images). We used the negative of the correlation coefficient between
176 the images from baseline and follow-up scans as a cost function to calculate the transformation matrix.
177 The cost function was minimized using a gradient descent method. The rotation matrix of the rigid body
178 transformation was used as the Jacobian for Eq. (4).

179 Please note that the SDFs calculated from Eq. (3) and (4) have “arbitrary units”. Therefore, the Z_1
180 constant in Eq. (4) had to be scaled to match the same unit of Z_0 in Eq. (3). This signal matching was
181 done using the sum of all diffusion-weighted images from two scans:

$$182 Z_1 = Z_0 \frac{\sum_r W_1(\phi(\mathbf{r}), 0)}{\sum_r W_0(\mathbf{r}, 0)} \quad (5)$$

183 The isotropic component of an SDF was then removed by subtracting its minimum values.

$$184 \quad \Psi_0'(\mathbf{r}, \hat{u}) = \Psi_0(\mathbf{r}, \hat{u}) - \min_{\hat{u}} \Psi_0(\mathbf{r}, \hat{u}) \quad (6)$$

$$185 \quad \Psi_1'(\mathbf{r}, \hat{u}) = \Psi_1(\mathbf{r}, \hat{u}) - \min_{\hat{u}} \Psi_1(\mathbf{r}, \hat{u}) \quad (7)$$

186 Equation (6) and (7) provide the anisotropic component of SDF (termed anisotropy hereafter) to
187 minimize the effect of free water diffusion (Yeh et al., 2013). It is noteworthy that this anisotropy
188 measurement has a different physical meaning from the fractional anisotropy (FA) calculated in DTI. FA
189 is a *ratio* between 0 and 1 calculated from diffusivities and has no unit. The anisotropic SDF has the
190 same physical unit of the SDF, which is the spin density of diffusing water.

191 **Tracking differences in the SDF**

192 To track differences along the existing fiber pathways, we first determined the local fiber orientations
193 using the peaks on the sum of $\Psi_0(\mathbf{r}, \hat{u})$ and $\Psi_1(\mathbf{r}, \hat{u})$, and then the anisotropy estimated from the
194 summed SDF was used to filter out noisy fibers and to define the termination of the white matter tracks,
195 as what had been done in conventional tractography (Yeh et al., 2013). The percentage difference in the
196 anisotropy between baseline and follow-up scans was then calculated (Fig. 1c):

$$197 \quad \Psi_d(\mathbf{r}, \hat{u}) = \frac{2(\Psi_1'(\mathbf{r}, \hat{u}) - \Psi_0'(\mathbf{r}, \hat{u}))}{\Psi_1'(\mathbf{r}, \hat{u}) + \Psi_0'(\mathbf{r}, \hat{u})} \times 100\% \quad (8)$$

198 The percentage changes in the anisotropy, $\Psi_d(\mathbf{r}, \hat{u})$, can have positive values (blue SDFs in Fig. 1c),
199 which indicates an increase in the density of anisotropic diffusion, or negative values (red SDFs in Fig.
200 1c), which indicates a decrease in the density of anisotropic diffusion.

201 An additional tracking-the-differences criterion was added to the fiber tracking algorithm to track the
202 exact segment with a decrease or an increase in the anisotropy greater than a *change* threshold,

203 Specifically, to track pathways with an increase of anisotropy, the additional criterion checked whether
204 the increase of anisotropy was greater than a predefined value of percentage change (e.g. 20%) and
205 continued tracking as long as the criterion was satisfied:

$$206 \quad \Psi_d(\mathbf{r}, \hat{\mathbf{a}}) > \theta^+ \quad (9)$$

207 where $\hat{\mathbf{a}}$ is the local fiber directions used in the fiber tracking algorithm. Similarly, to track pathways with
208 decreased anisotropy, the criteria continued tracking if the decrease of anisotropy was greater than a
209 predefined value of percentage change (e.g. -20%):

$$210 \quad \Psi_d(\mathbf{r}, \hat{\mathbf{a}}) < \theta^- \quad (10)$$

211 This allowed us to track two different sets of pathways, one for increased anisotropy, one for decreased
212 anisotropy. The other existing criteria in conventional tractography (e.g. seeding strategy, propagation
213 interval, angular threshold, length constraint...etc.) remained in effect as what has been used in the
214 generalized deterministic fiber tracking algorithm (Yeh et al., 2013). It is noteworthy that the angular and
215 anisotropy thresholds in the original tracking algorithm were still used in differential tractography to
216 eliminate noisy fiber and to ensure a correct white matter coverage. The criteria (9) or (10) (termed
217 “positive change threshold” and “negative change threshold”) served as *additional* constraints to limit the
218 findings to the exact segment of pathways with a substantial change in the anisotropy value.

219

220 In this study, the differential tractogram was obtained by placing a total of 5,000,000 seeding points in
221 the white matter. The angular threshold was randomly selected between 15 to 90 degrees. The step size
222 was 1 mm, and the anisotropy threshold was automatically determined by DSI Studio. Two iterations of
223 topology-informed pruning (Yeh et al., 2018) were applied to the tractography to remove noisy findings.

224 The above-mentioned setting was regularly used in conventional tractography. We tested differential
225 tractography with different values of change threshold (5%, 10%, 15% 50%) and length threshold (5
226 mm, 10 mm, 15 mm, ... 50 mm). Track with lengths shorter than the length threshold was discarded, and
227 the results of different length threshold and change threshold were compared to access its effect on the
228 sensitivity and specificity of differential tractography.

229 **Estimating false discovery rate using a sham setting**

230 Figure 2 illustrates the experimental design that allows for estimating the false discovery rate (FDR) of
231 differential tractography in individual scans. As shown in Fig. 2a, the baseline scan is compared with the
232 follow-up scan (upper row) using differential tractography to reveal tracks with decreased anisotropy (Fig.
233 2b, upper row). If a total of 5,000,000 tracking iterations are conducted, we can view each of them as an
234 independent hypothesis testing since each tracking iteration is done independently. The null hypothesis
235 is “there exists no track with a decrease in the anisotropy”. This null hypothesis will be rejected if the
236 track length is longer than a predefined length threshold (e.g. 40 mm). Each rejected hypothesis is thus
237 regarded as a “positive finding”, but here the finding can be either a true positive or false positive. As
238 shown by the example in the upper row of Fig. 2b, the number of tracks with a length longer than 40 mm
239 is 13947, meaning that there are 13947 rejected hypotheses as positive findings. These 13947 findings
240 include true positive and false positive, and we will need to estimate the number of false-positive findings
241 so that FDR can be estimated. To estimate the number of false-positive findings, a sham scan can be
242 acquired on the same day of the baseline scan or within a timeframe that no neuronal change is
243 expected (Fig. 2a, lower row), and thus any positive findings shown in the sham scan should be
244 false-positive findings. The sham scan is also compared with the baseline scan, and the same number
245 of 5,000,000 tracking iterations are conducted to see how many positive findings are generated. The
246 example in the lower row of Fig. 2b shows that the sham scan generates a total of 177 tracks with a

247 length longer than 40 mm, meaning that the estimated number of false-positive findings is 177. Using
248 this information, we can calculate the FDR, which is $177/13947=0.0127$ (Fig. 2c).

249 **Substitute sham**

250 In this retrospective study, we did not have an additional sham scan, and a “substitute sham” approach
251 was used. We assumed that there should be no increased track integrity during the disease course, any
252 findings showing *increased* anisotropy can be regarded as false-positive findings. Therefore, we can use
253 the number of tracks with *increased* anisotropy in the follow-up scan as a substitute for the sham scan.
254 Even if tracks with increased integrity do exist due to re-myelination, it will increase our estimated
255 number of false-positive findings. This means that the FDR estimated by this substitute sham approach
256 will be an upper bound of the actual FDR. Therefore, instead of reporting “FDR=0.0127”, the FDR
257 calculated using a substitute sham should be reported as “FDR \leq 0.0127”.

258 The processing pipeline for differential tractography and the quality control procedure is implemented in
259 DSI Studio (<http://dsi-studio.labsolver.org>). Documentation and source code to reproduce the same
260 result is also available on the website.

261 **Results**

262 **Neuronal injury reflected by a decrease of anisotropy**

263 Figure 3a shows the intermediate results of differential tractography applied to an MS patient with optic
264 neuritis (patient #1, demographics summarized in Table 1). The baseline scan was acquired right after
265 the onset, whereas the follow-up scan was acquired 6 months after. For each fiber orientation in a voxel,
266 differential tractography compares the anisotropy differences between two MRI scans in a common

267 subject space (Fig. 1a-1c). The fiber orientations with a decrease of anisotropy greater than 30% could
268 are plotted by red sticks in Fig. 3a. In the figure, most of the differences are distributed near the primary
269 visual pathways, whereas some spurious differences are randomly distributed throughout the entire
270 whiter matter regions, most likely due to local signal variations or registration error.

271

272 To eliminate these local spurious differences, the “tracking-the-difference” algorithm is applied to the
273 track and link all local differences together into continuous trajectories, and short fragments are
274 discarded using a length threshold of 40 mm (Fig. 3b). The rationale behind this length threshold is that
275 the local random error does not propagate along fiber pathways, whereas true findings due to neuronal
276 injury will form a continuous decrease of anisotropy along the fiber bundles. A length threshold will
277 effectively differentiate between them and help eliminate false results.

278 The left inset figure in Fig. 3b shows affected tracks in directional colors (red: left-right green:
279 anterior-posterior blue: superior-inferior), whereas the tracks in the right inset figure are color-coded by
280 the percentage decrease of anisotropy suggesting the severity of neuronal injury (yellow: 0% decrease
281 red: 70% decrease). In overall, the differential tractogram in Fig. 3b reveals a heterogeneous decrease
282 of anisotropy between 20% to 50%. All findings are in the bilateral primary visual pathways or their
283 collateral connections. The location of the finding matches well with the patient’s medical history of
284 visual field loss in both left and right quadrants. The topology of affected pathways seems to present a
285 ripple effect: not only the primary visual pathway is affected, but also certain collateral connections to the
286 visual cortex has shown a decrease in the anisotropy. Although this patient was fully recovered from the
287 symptoms during the follow-up scan (brief medical history in the Supplementary materials), differential
288 tractography still captures subclinical change near the bilateral optic radiation.

289 We further compare differential tractography with conventional voxel-wise statistics. Figure 3c shows the
290 axial mapping of anisotropy differences for each voxel using the same data. The red regions are voxels
291 with anisotropy decrease greater than 30%, and the numerous fragments can be observed across the
292 entire brain regions. Those fragments could be due to local random error and thus may not be true
293 findings. This illustrates a typical limitation of a voxel-based imaging biomarker, and there is no pathway
294 information to assist diagnostic evaluation. In comparison, the differential tractogram in Fig. 3b provides
295 track-based imaging biomarkers that can easily assist diagnostic evaluation by offering trajectories
296 information. The findings can be associated with an anatomical pathway to infer the functional
297 correlation.

298 **Conventional tractography versus differential tractography**

299 Figure 4 compares conventional tractography (Fig. 4a) with differential tractography (Fig. 4b) on another
300 MS patient with optic neuritis (patient #2 demographics summarized in Table 1). The conventional
301 tractography was generated using the baseline scan, whereas the differential tractography was
302 configured to map pathways with more than a 30% decrease in anisotropy with a length threshold of 40
303 mm. The trajectories in Fig. 4a and Fig. 4b are both colored-coded with directional colors (red: left-right
304 green: anterior-posterior blue: superior-inferior). The first row shows tractography viewing from the top,
305 whereas the second rows show from the left. The conventional tractography in Fig. 4a visualizes the
306 trajectories of the entire brain fiber pathways, and there is no gross anomaly visible from the
307 tractography that may suggest a major neurological disorder. This is expected because, at the early
308 stage of multiple sclerosis, the patient usually does not present a gross structural change that can be
309 readily identified in conventional tractography. In comparison, the different tractography in Fig. 4b
310 pinpoints the location of affected pathways in the bilateral primary visual pathway near the visual cortex.

311 The location matches well with the patient's disease presentation of optic neuritis, whereas conventional
312 tractography in Fig. 4a shows no clue to this critical information.

313 **Reliability assessment**

314 We further use patient #1 and a 42-year-old normal subject as the examples to show how the reliability
315 of differential tractography findings can be quantified using a sham setting. Both the follow-up scans of
316 these two subjects were acquired 6 months after the baseline scans. Figure 5a is the differential
317 tractogram of patient #1 showing pathways with an increase or decrease anisotropy greater than 30% at
318 different length thresholds, whereas Fig. 5b is the same analysis applied to a healthy subject. Only the
319 decreased anisotropy in patient #1 (lower row in Fig. 5a) contains possible true findings for neuronal
320 injury, whereas other rows in Fig. 5a and Fig. 5b are all false-positive results due to either physiological
321 noises (cardiovascular or respiratory) or phase distortion artifact. Most false findings can be effectively
322 removed using a longer length threshold, and there is a trade-off between sensitivity and specificity
323 controlled by the length threshold. A longer length threshold renders a more specific result with the
324 expense of losing meaningful findings in shorter segments, whereas a shorter length threshold allows for
325 more findings with a risk of taking false results. To quantify the reliability of findings in the lower row of
326 Fig. 5a, we used the total number of findings at the upper row of Fig. 5a as an estimation for the number
327 of false findings. This assumes that the random error will produce a similar number of false findings in
328 both rows and allows us to estimate FDR.

329 Figure 5c and 5d illustrate the FDR calculation process. Figure 5c lists the number of findings at different
330 length thresholds and the change thresholds for patient #1 (upper two tables) and the normal subject
331 (lower two tables). For example, a negative change threshold of 30% means that the tracking algorithm
332 will track only the fiber orientations with a decrease of anisotropy greater than 30%. The tables on the
333 left are numbers of findings with decreased anisotropy, whereas those on the right are numbers of

334 findings with increased anisotropy. The green colors in the table are those with a larger number of
335 findings, whereas the red colors indicate a smaller number. The tables of the patient show a
336 substantially larger number of findings with decreased anisotropy caused by the disease. In comparison,
337 the two tables of the control subject are substantially similar, and the false results are equally distributed
338 in both tables. This result supports the usage of the “substitute sham” approach mentioned in the
339 Material and Methods section: we can reasonably use the findings with increased anisotropy (the table
340 on the right) of the same subject to estimate the number of false findings for calculating FDR.

341 Figure 5d shows the FDR of patient #1’s findings calculated using the “substitute sham” (the increase of
342 anisotropy results from the same subject). The resulting table shows a trade-off between sensitivity and
343 specificity controlled by both the length threshold and change threshold. A length threshold of 30~40 mm
344 and a change threshold at 20~30% decrease of anisotropy provides us an FDR around 0.01, suggesting
345 that around 1% of the tracks shown in the differential tractogram are false results. We can use these two
346 thresholds to leverage sensitivity and specificity. For example, lower thresholds are geared toward
347 higher sensitivity to explore potential neuronal injury, whereas higher thresholds can provide a
348 confirmatory answer to the axonal damage. The optimal setting can be different based on the disease
349 condition, scan interval, and purposes (e.g. exploratory or confirmatory).

350 **Differential tractography on patients with neurological diseases**

351 We further apply differential tractography to patients with different neurological disorders in Fig. 6 and
352 list the FDR of these findings in Table 2. The scan subjects include patients with MS (#1, #2), HD (#3,
353 #4), ALS (#5), and epilepsy (#6). The first three rows show the differential tractograms in three views
354 (left sagittal from left, coronal from the front and axial from top) using directional colors, where the last
355 row shows the differential tractogram with yellow-red colors representing the percentage decrease of
356 anisotropy.

357 The first notable finding comparing MS patients #1 and #2 is that the volume of affected pathways and
358 their decrease of anisotropy reflect the severity of their clinical symptoms. The medical history of patient
359 #1 (Supplementary Materials) indicates a more severe drop in visual acuity to 20/400 in addition to her
360 visual field defect in all quadrants, while patient #2 only had a decrease of visual acuity to 20/125 with
361 only superior altitudinal visual field defect (Table 1 and Supplementary Materials). The greater severity in
362 patient #1 is reflected by a larger volume of affected pathways diffusion (patient #1: 55681.6 mm³,
363 patient #2: 26124 mm³) and a greater decrease of anisotropy shown in the last row. This suggests that
364 differential tractography has a quantitative potential to evaluate disease severity using either the volume
365 of affected tracks or the decrease of their anisotropy.

366 The differential tractogram of HD patients #3 and #4 in Fig. 6 both shows affected pathways around the
367 stratum. This matches well with the common understanding that striatal pathways are usually involved in
368 Huntington's disease. Moreover, the differential tractogram in patient #4 has a greater involvement
369 extending to brainstem and cerebellum, suggesting a worse motor performance. This seems to match
370 the patient's medical history of a higher motor score of 64 (Table 1 and Supplementary Materials). The
371 patient also had more asymmetric dystonia, matching the asymmetry presentation of the differential
372 tractography.

373 Patient #5 in Fig. 6 is an ALS patient. It is noteworthy that this patient had mostly lower motor neuron
374 symptoms (weakness), and thus might not have positive findings in the brain. The differential tractogram
375 of this patient were obtained using a 15% negative change threshold because a threshold of 30%
376 yielded no findings. Differential tractography reveals only a minor decrease in this patient (other cases in
377 Fig. 6 have mostly greater than 30% decrease). This could be explained by the fact that the patient had
378 predominately lower motor neuron symptoms affecting predominately peripheral nerves. Therefore, the
379 findings in the central nervous system could be only subclinical. Nonetheless, as we lowered the change

380 threshold to 15%, differential tractography showed affected pathways in the right lower corticospinal
381 pathway (blue-purple colored), superior cerebellar peduncle, and posterior corpus callosum, as shown in
382 Fig. 6. The right corticospinal pathway involvement seems to match the patient's history of left side
383 involvement, but it is noteworthy that the FDR of these findings were much higher (FDR~0.2 in Table 2),
384 meaning that around 1/5 of the findings are false positives. The corpus callosum and occipital lobe
385 findings could be subclinical damage and did not present any clinical symptoms (to be discussed in the
386 Discussion section).

387 Patient #6 was a 51-year-old male with right anterior lobectomy. He was previously an epileptic patient
388 with recurrent epilepsy (Supplementary Materials). The MRI scans were done before the surgery and
389 one year after the surgery. Differential tractography accurately locates the location of the surgical
390 resection in the mesial structures and approximately 5 cm of the anterior temporal neocortex. Moreover,
391 it further reveals the pathways that were affected by the resection. While the surgical resection only
392 removed part of the temporal gyri, the affected pathways involve much greater connection networks.
393 Furthermore, the last row shows that the decrease of anisotropy is mostly greater than 50%, indicating a
394 greater axonal loss due to the surgical removal of the brain tissue.

395 The last column in Fig. 6 shows the differential tractogram of a control. We applied the same settings to
396 examine how differential tractography may capture false results. The result shows a mild decrease of
397 anisotropy as presented by yellow tracks in the last row, a clue that the change may be a false positive
398 result. Furthermore, there are only 74 findings located at the prefrontal cortex, and these findings are
399 relatively insignificant compared to those of the patient population that shows thousands of findings
400 (Table 2). Moreover, the location of the findings is known to be heavily affected by the phase distortion
401 artifact, and the findings could be due to the different level of distortion between the repeat scans.
402 However, it is noteworthy that the calculated FDR will be 0 in this case because there are no findings

403 with increase anisotropy for this control subject. This result suggests that the FDR estimation still have
404 its limitation if the number of findings is sufficiently small. The interpretation of differential tractography
405 results still needs to consider the percentage decrease of anisotropy, the total number of findings, and
406 possible sources of imaging artifact.

407 In general, the findings in Fig. 6 allows us to quickly differentiates the possible locations of neuronal
408 injury and evaluate the severity. The affected pathways in MS, HD, and ALS patients show distinctly
409 different topology, allowing for differential diagnosis or prognosis evaluation. Table 2 further shows how
410 we can use the sham setting to calculate FDR to evaluate the reliability of the results.

411 **Performance difference after dropping high b-value acquisitions**

412 We further investigate whether high b-value signals contribute to the detection power of differential
413 tractography. In this study, we acquired 22 b-values ranging from 0 to 7,000 s/mm², but most diffusion
414 MRI studies would acquire b-values between 1,000 and 3,000 s/mm² because higher b-values result in
415 poorer signal-to-noise (SNR) ratio. This can be observed in Fig. 7a showing the diffusion-weighted
416 images at different b-values from patient #1. It is thus of a practical consideration to limit the b-values
417 under a certain maximum value. To examine whether the high b-value acquisition is necessary for
418 differential tractography, we repeated the same differential tractography analysis but used only the
419 signals with b-values between 0 and 3,000 s/mm² (a total of 85 sampling directions). The reduced
420 dataset is very similar to the scheme acquired in a previous study (Wang et al., 2011).

421 Fig. 7b shows a qualitative comparison on subject #1 before and after dropping high b-value signals.
422 The location of the findings is mostly consistent; however, dropping high b-values results in substantial
423 loss of the findings (annotated by the red circle). This implies that certain stages of neuronal injury can
424 only be detected by very high b-values. The quantitative comparison is listed in Table 3. As shown in the

425 table, there is a unanimous drop in positive findings for all patients, ranging from 38% decrease to 97%
426 decrease, while the false findings in the normal subject increased by 7 times. Consequently, patients #1
427 and #3 have a dramatic FDR increase from less than 0.05 to more than 0.3, making the findings not
428 statistically reliable. It seems that differential tractography using only low b-value signals is more
429 sensitive to physiological variations, whereas differential tractography using both high and low b-value
430 signals are more reliable in detecting are more specific to neuronal injury. This could be explained by the
431 fact that the low b-value images in Fig. 7a have more signal contribution from free water diffusion in
432 ventricles and subarachnoid space, whereas high b-value images only have signals from restricted
433 diffusion in the core white matter. Excluding high b-value signals will shift the focus to free water
434 diffusion and lead to more false-positive results. The overall result supports the necessity of including
435 high b-value acquisition for differential tractography to detect neuronal injury.

436 **Discussion**

437 Here we report a novel tractography method to reveal fiber pathways affected by a neuronal injury. We
438 found that differential tractography could serve as a track-based biomarker to provide localization of
439 neuronal injury and allow for quantifying its severity using the decrease of anisotropy and the total
440 volume of affected pathways. The estimated FDR further offered reliability information to interpret the
441 results, and the findings correlated well with clinical presentations of each individual.

442 **Comparison with other methods**

443 Diffusion MRI fiber tracking can be viewed as a clustering process that is directionally sensitive. By using
444 spatial relations across multiples voxels, the tracking-the-difference strategy used in differential

445 tractography has the potential to differentiate true findings from local errors, since neuronal injury will
446 propagate along axonal fibers while local error stays locally. This tracking-the-difference strategy is
447 conceptually similar to clustering used in voxel-based morphometry (Ashburner and Friston, 2000) or
448 fMRI studies (Woo et al., 2014), which groups voxel-wise statistics into clusters to achieve greater
449 statistical power. The difference is that the clustering used in previous studies did not consider local fiber
450 orientations and would include voxels at all possible neighboring directions, whereas differential
451 tractography only allows findings along the fiber pathways. This improvement is similar to those using
452 fiber geometry to increase specificity (Raffelt et al., 2017; Zhang et al., 2018), and It is likely that this
453 structural restriction may achieve a better specificity than a regular clustering approach.

454 **Optimal b-table for differential tractography**

455 The diffusion MRI acquisitions played a critical role to boost the sensitivity of differential tractography.
456 Our result shows that acquisitions using only b-values lower than 3,000 s/mm² may have a limited
457 detection power for early neuronal injury. We also tested differential tractography on existing DTI data,
458 and the preliminary result (not reported here) also showed a substantially higher rate of false findings.
459 This is not surprising because a typical DTI acquisition only acquires only one b-value of 1,000~2,000
460 s/mm² at 30~60 directions, whereas in this study, we acquired 22 b-values from 0 to 7,000 s/mm² at 257
461 directions. It is likely that early axonal injury affects mostly restricted diffusion and can only be reliably
462 captured if a wider range of b-value is acquired with enough diffusion sampling directions.

463 Multishell-acquisition could also be used by differential tractography to detect neuronal injury, but its
464 challenges are how to ensure a homogeneous sampling density in the q-space acquisition to make the
465 acquisition “rotation invariant”. In addition, most multi-shell acquisitions have an over-sampling problem
466 within each shell and under-sampling problem between shells, which can be observed by plotting the

467 sampling points in the q-space. Consequently, the inter-shell coverage may not be sufficient enough to
468 capture a variety of diffusion patterns, while the intra-shell signals can be easily interpolated due to
469 oversampling, meaning that there is redundancy which can be further reduced to save scanning time.

470 The q-space grid sampling used in this study seems to be the method of choice for differential tractography
471 because it has uniform sampling density in the q-space and covers 22 different b-values. This
472 maximized the chance to detect a variety of diffusion pattern that could be altered during the disease
473 process. Q-space imaging used to be criticized for its lengthy scanning time; however, after the
474 introduction of the multi-band sequences, the updated q-space grid sampling scheme could be acquired
475 within 12 minutes for 256 directions and 6 minutes for 128 directions, making it highly feasible for clinical
476 studies. The exact steps to reproduce these two q-space grid acquisitions are documented on the DSI
477 Studio website (<http://dsi-studio.labsolver.org/>).

478 **Anisotropy measurement for differential tractography**

479 The anisotropy used in this study is not the commonly used FA provided by DTI. FA is a voxel-wise
480 measurement, and it does not selectively quantify the anisotropy at different fiber population within the
481 same voxel. In comparison, the anisotropy in this study can quantify the anisotropy for each fiber
482 population at different directions. This results in greater specificity to individual's connectivity patterns
483 (Yeh et al., 2016) and better performance in handling the partial volume effect (Yeh et al., 2013).

484 **Subclinical findings**

485 Another interesting result we observed in this study is that differential tractography seems to capture
486 subclinical findings: certain pathways could be injured without any obvious clinical symptoms reported
487 by patients. For example, the two MS patients shown in Fig. 5 were symptom-free during the follow-up

488 scans after the steroid treatments (Supplementary Materials); however, differential tractography still
489 captures a substantial number of findings related to the primary visual pathways, and the decrease of
490 the anisotropy diffusion correlates well with the severity of the initial clinical presentation. Similarly, by
491 lowering the detection threshold, the ALS patient in Fig. 5 also shows substantial involvement in the
492 posterior corpus callosum that connects to the occipital lobe. Although there is no clinical presentation of
493 this patient associated with the findings, subclinical callosal damage for ALS patients is not uncommon
494 (Filippini et al., 2010), and there are also studies suggested subclinical involvement of occipital lobe in
495 the ALS patients (Loewe et al., 2017; Zhang et al., 2017). The ability to capture subclinical findings has a
496 profound clinical implication. It suggests that differential tractography is sensitive enough to provide
497 additional evaluation value on top of existing clinical scales and scores. This may facilitate the
498 development of new treatment to target early subclinical change that may end up with irreversible
499 damage.

500 **Limitations and possible pitfalls**

501 There are limitations in differential tractography. Differential tractography only works on longitudinal
502 scans of the same subject and only reflects the change of anisotropy within the time frame of the repeat
503 scans. It cannot access track integrity in a cross-sectional setting, nor does it able to detect any
504 abnormality or axonal injury prior to the baseline scans. Furthermore, differential tractography still has
505 false results if the artifact also propagates coincidentally along a fiber pathway. The parallel imaging or
506 eddy current artifact often gives rise to straight lines near the brain surface but may appear like a
507 spuriously legitimate connection. Misalignment between baseline and follow-up scans can also generate
508 a false result, and it can happen due to registration error or brain tissue shift after surgical intervention.

509 There are still other possible causes of false results. The subjects may have substantial movement in
510 the follow-up scan, but not in the study or sham scan. There may be inconsistency in image acquisition
511 between repeat scans such as changing the head coils or scanning protocol. Both scenarios can
512 produce spurious findings, and thus a series of quality control is always needed to avoid these getting
513 false results. Furthermore, the findings in differential tractography still need to be validated against
514 neuroanatomy. Spurious findings often appear near the brain surface with odd trajectories (straight
515 lines), while true findings tend to follow the trajectories of well-known neuroanatomical pathways. Prior
516 neuroanatomy knowledge may help exclude false results from true findings.

517 There are also limitations in the reliability assessment. The sham setting in this study uses only one scan,
518 and thus the calculated FDR only considered false results due to local random error (e.g. noise which
519 randomly occurs at each imaging voxel) and does not include those due to systematic errors (errors that
520 affects all imaging voxels simultaneously) such as subject movements, coil quality, or signal drift. To
521 detect these systematic errors, we introduced four quality-control routines in the Material and Methods
522 section to discard scans that had a substantial amount of systematic errors. Moreover, we did not
523 acquire an additional sham scan in this study and used the “substitute sham” approach. The substitute
524 sham approach can overestimate the number of false results due to a genuine increase of anisotropy
525 (e.g. re-myelination after recovering from a neuronal injury). The consequence is that the FDR could be
526 higher than the actual value, and the reliability of the findings could be underestimated, leading to a risk
527 of missing meaningful findings.

528 Last, the diffusion MRI protocol in this study could be further optimized. Our result showed that high
529 b-value played an important role in boosting the sensitivity of differential tractography, but the optimal
530 value range still needs further investigation. Moreover, this study did not utilize the recent multi-band
531 acquisition to reduce the scanning time, and future studies will utilize multi-band sequences to make

532 differential tractography more feasible for clinical applications (e.g. 6-minutes grid-128 and 12-minute
533 grid-256 acquisitions mentioned in the previous paragraphs).

534 **Clinical applications**

535 Differential tractography can be used in differential diagnosis or prognostic evaluation after treatment or
536 intervention. Neurologists can use it to differentiate the cause of a neurological disorder as patients with
537 different neurological disorders will present distinctly different spatial patterns in their affected pathways.
538 The location will provide a clue about the possible causes to resolve difficult clinical cases. This is
539 otherwise not achievable in structural MRI unless a gross lesion or atrophy is visible in the late stage of
540 neuronal injury. Another application of differential tractography is for evaluating an intervention or
541 treatment. Differential tractography can provide an objective quantitation that is directly comparable
542 across subjects and less susceptible to observer differences. It could minimize variance due to evaluator
543 differences and increase effect size in comparison with the conventional evaluation conducted by
544 patients or neurologists. This opens a gate for early treatments to restore subclinical injuries before
545 those injuries accumulate to become a major functional deficit.

546 **Acknowledgments**

547 The research reported in this publication was partly supported by NIMH of the National Institutes of
548 Health under award number R56MH113634. The content is solely the responsibility of the authors and
549 does not necessarily represent the official views of the National Institutes of Health. The MRI scans were
550 partly supported by the Walter L. Copeland Fund of The Pittsburgh Foundation.

551 **References**

- 552 Abhinav, K., Yeh, F.C., El-Dokla, A., Ferrando, L.M., Chang, Y.F., Lacomis, D., Friedlander, R.M.,
553 Fernandez-Miranda, J.C., 2014. Use of diffusion spectrum imaging in preliminary longitudinal
554 evaluation of amyotrophic lateral sclerosis: development of an imaging biomarker. *Front Hum Neurosci*
555 *8*, 270.
- 556 Ashburner, J., Friston, K.J., 2000. Voxel-based morphometry--the methods. *Neuroimage* *11*, 805-821.
- 557 Basser, P.J., Mattiello, J., LeBihan, D., 1994. Estimation of the effective self-diffusion tensor from the
558 NMR spin echo. *J Magn Reson B* *103*, 247-254.
- 559 Budde, M.D., Xie, M., Cross, A.H., Song, S.K., 2009. Axial diffusivity is the primary correlate of
560 axonal injury in the experimental autoimmune encephalomyelitis spinal cord: a quantitative pixelwise
561 analysis. *J Neurosci* *29*, 2805-2813.
- 562 Callaghan, P.T., 1991. *Principles of Nuclear Magnetic Resonance Microscopy*. Oxford University Press.
- 563 Filippini, N., Douaud, G., Mackay, C.E., Knight, S., Talbot, K., Turner, M.R., 2010. Corpus callosum
564 involvement is a consistent feature of amyotrophic lateral sclerosis. *Neurology* *75*, 1645-1652.
- 565 Glasser, M.F., Smith, S.M., Marcus, D.S., Andersson, J.L., Auerbach, E.J., Behrens, T.E., Coalson, T.S.,
566 Harms, M.P., Jenkinson, M., Moeller, S., Robinson, E.C., Sotiropoulos, S.N., Xu, J., Yacoub, E.,
567 Ugurbil, K., Van Essen, D.C., 2016. The Human Connectome Project's neuroimaging approach. *Nat*
568 *Neurosci* *19*, 1175-1187.
- 569 Henf, J., Grothe, M.J., Brueggen, K., Teipel, S., Dyrba, M., 2018. Mean diffusivity in cortical gray
570 matter in Alzheimer's disease: The importance of partial volume correction. *Neuroimage Clin* *17*,
571 579-586.
- 572 Huisman, T.A., Schwamm, L.H., Schaefer, P.W., Koroshetz, W.J., Shetty-Alva, N., Ozsunar, Y., Wu, O.,
573 Sorensen, A.G., 2004. Diffusion tensor imaging as potential biomarker of white matter injury in diffuse
574 axonal injury. *AJNR Am J Neuroradiol* *25*, 370-376.
- 575 Loewe, K., Machts, J., Kaufmann, J., Petri, S., Heinze, H.J., Borgelt, C., Harris, J.A., Vielhaber, S.,
576 Schoenfeld, M.A., 2017. Widespread temporo-occipital lobe dysfunction in amyotrophic lateral sclerosis.
577 *Sci Rep* *7*, 40252.
- 578 Maier-Hein, K.H., Neher, P.F., Houde, J.C., Cote, M.A., Garyfallidis, E., Zhong, J., Chamberland, M.,
579 Yeh, F.C., Lin, Y.C., Ji, Q., Reddick, W.E., Glass, J.O., Chen, D.Q., Feng, Y., Gao, C., Wu, Y., Ma, J.,
580 Renjie, H., Li, Q., Westin, C.F., Deslauriers-Gauthier, S., Gonzalez, J.O.O., Paquette, M., St-Jean, S.,
581 Girard, G., Rheault, F., Sidhu, J., Tax, C.M.W., Guo, F., Mesri, H.Y., David, S., Froeling, M.,
582 Heemskerk, A.M., Leemans, A., Bore, A., Pinsard, B., Bedetti, C., Desrosiers, M., Brambati, S., Doyon,
583 J., Sarica, A., Vasta, R., Cerasa, A., Quattrone, A., Yeatman, J., Khan, A.R., Hodges, W., Alexander, S.,

584 Romascano, D., Barakovic, M., Auria, A., Esteban, O., Lemkaddem, A., Thiran, J.P., Cetingul, H.E.,
585 Odry, B.L., Mailhe, B., Nadar, M.S., Pizzagalli, F., Prasad, G., Villalon-Reina, J.E., Galvis, J.,
586 Thompson, P.M., Requejo, F.S., Laguna, P.L., Lacerda, L.M., Barrett, R., Dell'Acqua, F., Catani, M.,
587 Petit, L., Caruyer, E., Daducci, A., Dyrby, T.B., Holland-Letz, T., Hilgetag, C.C., Stieltjes, B.,
588 Descoteaux, M., 2017. The challenge of mapping the human connectome based on diffusion
589 tractography. *Nat Commun* 8, 1349.

590 Melonakos, E.D., Shenton, M.E., Rathi, Y., Terry, D.P., Bouix, S., Kubicki, M., 2011. Voxel-based
591 morphometry (VBM) studies in schizophrenia-can white matter changes be reliably detected with VBM?
592 *Psychiatry Res* 193, 65-70.

593 Raffelt, D.A., Tournier, J.D., Smith, R.E., Vaughan, D.N., Jackson, G., Ridgway, G.R., Connelly, A.,
594 2017. Investigating white matter fibre density and morphology using fixel-based analysis. *Neuroimage*
595 144, 58-73.

596 Rovira, A., Wattjes, M.P., Tintore, M., Tur, C., Yousry, T.A., Sormani, M.P., De Stefano, N., Filippi, M.,
597 Auger, C., Rocca, M.A., Barkhof, F., Fazekas, F., Kappos, L., Polman, C., Miller, D., Montalban, X.,
598 group, M.s., 2015. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in
599 multiple sclerosis-clinical implementation in the diagnostic process. *Nat Rev Neurol* 11, 471-482.

600 Schilling, K.G., Yeh, F.C., Nath, V., Hansen, C., Williams, O., Resnick, S., Anderson, A.W., Landman,
601 B.A., 2019. A fiber coherence index for quality control of B-table orientation in diffusion MRI scans.
602 *Magn Reson Imaging* 58, 82-89.

603 Song, S.K., Sun, S.W., Ramsbottom, M.J., Chang, C., Russell, J., Cross, A.H., 2002. Demyelination
604 revealed through MRI as increased radial (but unchanged axial) diffusion of water. *Neuroimage* 17,
605 1429-1436.

606 Song, S.K., Yoshino, J., Le, T.Q., Lin, S.J., Sun, S.W., Cross, A.H., Armstrong, R.C., 2005.
607 Demyelination increases radial diffusivity in corpus callosum of mouse brain. *Neuroimage* 26, 132-140.

608 Tabrizi, S.J., Langbehn, D.R., Leavitt, B.R., Roos, R.A., Durr, A., Craufurd, D., Kennard, C., Hicks,
609 S.L., Fox, N.C., Scahill, R.I., Borowsky, B., Tobin, A.J., Rosas, H.D., Johnson, H., Reilmann, R.,
610 Landwehrmeyer, B., Stout, J.C., investigators, T.-H., 2009. Biological and clinical manifestations of
611 Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.
612 *Lancet Neurol* 8, 791-801.

613 Tabrizi, S.J., Reilmann, R., Roos, R.A., Durr, A., Leavitt, B., Owen, G., Jones, R., Johnson, H.,
614 Craufurd, D., Hicks, S.L., Kennard, C., Landwehrmeyer, B., Stout, J.C., Borowsky, B., Scahill, R.I.,
615 Frost, C., Langbehn, D.R., investigators, T.-H., 2012. Potential endpoints for clinical trials in
616 premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month
617 observational data. *Lancet Neurol* 11, 42-53.

618 Wang, Y., Wang, Q., Haldar, J.P., Yeh, F.C., Xie, M., Sun, P., Tu, T.W., Trinkaus, K., Klein, R.S.,
619 Cross, A.H., Song, S.K., 2011. Quantification of increased cellularity during inflammatory
620 demyelination. *Brain* 134, 3590-3601.

621 Wattjes, M.P., Rovira, A., Miller, D., Yousry, T.A., Sormani, M.P., de Stefano, M.P., Tintore, M.,
622 Auger, C., Tur, C., Filippi, M., Rocca, M.A., Fazekas, F., Kappos, L., Polman, C., Frederik, B., Xavier,
623 M., group, M.s., 2015. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI
624 in multiple sclerosis--establishing disease prognosis and monitoring patients. *Nat Rev Neurol* 11,
625 597-606.

626 Wedeen, V.J., Rosene, D.L., Wang, R., Dai, G., Mortazavi, F., Hagmann, P., Kaas, J.H., Tseng, W.Y.,
627 2012. The geometric structure of the brain fiber pathways. *Science* 335, 1628-1634.

628 Werring, D.J., Clark, C.A., Barker, G.J., Thompson, A.J., Miller, D.H., 1999. Diffusion tensor imaging
629 of lesions and normal-appearing white matter in multiple sclerosis. *Neurology* 52, 1626-1632.

630 Werring, D.J., Toosy, A.T., Clark, C.A., Parker, G.J., Barker, G.J., Miller, D.H., Thompson, A.J., 2000.
631 Diffusion tensor imaging can detect and quantify corticospinal tract degeneration after stroke. *J Neurol*
632 *Neurosurg Psychiatry* 69, 269-272.

633 Woo, C.W., Krishnan, A., Wager, T.D., 2014. Cluster-extent based thresholding in fMRI analyses:
634 pitfalls and recommendations. *Neuroimage* 91, 412-419.

635 Yeh, F.C., Panesar, S., Barrios, J., Fernandes, D., Abhinav, K., Meola, A., Fernandez-Miranda, J.C.,
636 2018. Automatic Removal of False Connections in Diffusion MRI Tractography Using
637 Topology-Informed Pruning (TIP). *Neurotherapeutics*.

638 Yeh, F.C., Tseng, W.Y., 2011. NTU-90: a high angular resolution brain atlas constructed by q-space
639 diffeomorphic reconstruction. *Neuroimage* 58, 91-99.

640 Yeh, F.C., Verstynen, T.D., Wang, Y., Fernandez-Miranda, J.C., Tseng, W.Y., 2013. Deterministic
641 diffusion fiber tracking improved by quantitative anisotropy. *PLoS ONE* 8, e80713.


642 Yeh, F.C., Vettel, J.M., Singh, A., Poczos, B., Grafton, S.T., Erickson, K.I., Tseng, W.I., Verstynen,
643 T.D., 2016. Quantifying Differences and Similarities in Whole-Brain White Matter Architecture Using
644 Local Connectome Fingerprints. *PLoS Comput Biol* 12, e1005203.

645 Yeh, F.C., Wedeen, V.J., Tseng, W.Y., 2010. Generalized q-sampling imaging. *IEEE Trans Med*
646 *Imaging* 29, 1626-1635.

647 Zhang, F., Wu, W., Ning, L., McAnulty, G., Waber, D., Gagoski, B., Sarill, K., Hamoda, H.M., Song, Y.,
648 Cai, W., Rathi, Y., O'Donnell, L.J., 2018. Suprathreshold fiber cluster statistics: Leveraging white matter
649 geometry to enhance tractography statistical analysis. *Neuroimage* 171, 341-354.

650 Zhang, Y., Fang, T., Wang, Y., Guo, X., Alarefi, A., Wang, J., Jiang, T., Zhang, J., 2017. Occipital
651 cortical gyrification reductions associate with decreased functional connectivity in amyotrophic lateral
652 sclerosis. *Brain Imaging Behav* 11, 1-7.

653




654

655 **Fig. 1**

656 The flow chart of differential tractography. (a) The baseline and follow-up scans of the same subject are
657 spatially aligned, and the diffusion signals are scaled to the same unit. (b) The spin distribution function
658 (SDF) from two scans are reconstructed in the same common subject space. (c) The difference in the
659 anisotropic component of SDF is computed for each fiber orientation. (d) Increased and decreased
660 anisotropy values are separated to guide a “tracking-the-difference” algorithm. (e) Differential
661 tractography shows the exact segment of tracks with increased and decreased anisotropy, respectively.
662 The tracks with decreased anisotropy suggest possible neuronal injury, whereas the number of tracks
663 with increased anisotropy can be used to estimate the number of false findings.

664




665

666 **Fig. 2**

667 Diagram showing the sham setting for calculating the false discovery rate (FDR). (a) The baseline scan
668 is compared with a follow-up scan (upper row) and a sham scan (lower row), respectively. The follow-up
669 scan is often acquired months after the baseline scan to capture the true positive findings, whereas the
670 sham scan can be a repeat scan on the same day or any scan setting that ensures the findings are all
671 false positives. (b) The number of findings from the follow-up scan (upper row) includes both true and
672 false positives, whereas the number from the sham scan (lower row) include only false-positive findings.
673 (c) These two numbers can be used to estimate FDR.

674




675


676 **Fig. 3**

677 Differential tractography of a multiple sclerosis patient with the first episode of optic neuritis. (a) The
678 intermediate result of differential tractography shows red sticks indicating local fiber orientations with a
679 negative change threshold of 30% between repeat scans. The sticks are mostly distributed along the
680 primary visual pathways, while sporadic false findings can also be found throughout the entire whiter
681 matter regions due to local signal variations. (b) The red sticks are tracked and connected into
682 continuous trajectories, whereas the other unaffected parts of the white matter pathways are ignored.
683 The resulting 3D presentation is the differential tractogram of the patient showing the exact segment of
684 pathways with a substantial decrease in anisotropy. The tractography can be rendered by directional
685 colors (left) or severity-coded color (right) to provide information about the spatial location, and the
686 severity of the axonal damage can be quantified by percentage decrease of anisotropic diffusion. (c) The
687 same data analyzed by voxel-based differences show numerous fragmented findings possibly due to
688 numerous local random error. There is no track information to assist correlating structure with a function
689 and differentiating true findings from false ones.

a



b




691

692 **Fig. 4**

693 Conventional tractography compared with differential tractography on a multiple sclerosis patient with
694 the first episode of optic neuritis. (a) Conventional tractography shows all existing fiber pathways in the
695 human brain and is insensitive to any subtle decrease in the diffusion property. (b) Differential
696 tractography ignores unaffected regions and shows the exact segments of the pathways that have a
697 substantial decrease of anisotropy quantified between repeat scans of the same individual.


698



700 **Fig. 5**

701 Reliability assessment of differential tractography using the length threshold. (a) Differential
702 tractography is applied to a multiple sclerosis patient at different length thresholds. Only the tracks with
703 decreased anisotropy in the patient may contain true positive findings. A longer length threshold (e.g. >
704 40mm) can reduce false findings at the expense of sensitivity, whereas a shorter threshold may
705 introduce more false results. (b) Differential tractography is applied to a normal subject, and any findings
706 in the normal subject are false positives for neuronal injury. (c) The numbers of findings at different
707 length thresholds and change thresholds are listed in tables. The patient has substantially large
708 numbers of tracks with decreased anisotropy, suggesting a possible neurological injury. In comparison,
709 the normal subject has similar numbers of tracks with increased and decreased anisotropy. (d) False
710 discovery rate (FDR) of the findings in a patient can be calculated by using the patient's own numbers of
711 tracks with increased anisotropy as an estimation of the number of false findings. This allows for
712 adjusting the sensitivity and specificity of differential tractography and quantifying the reliability at
713 different length and change thresholds.

714




716 **Fig. 6**

717 Differential tractograms of patients with different neurological disorders in comparison with a normal
718 subject. The results were generated automatically without expert selection. The differential tractograms
719 of the two MS patients match well with their clinical presentation of optic neuritis. Patient #1 has a much
720 severer drop in visual acuity, which can be quantitatively reflected by her larger the volume of the
721 findings and a greater percentage decrease of the anisotropy along the affected pathways. The
722 differential tractograms of the two Huntington diseases show extensive affected striatal pathways.
723 Patient #4 had more asymmetric dystonia, matching the asymmetry presentation of the differential
724 tractography. The ALS patient had lower motor neuron presentation of left-hand weakness, matching
725 the finding of right lower corticospinal pathways in differential tractography. The epileptic patients
726 received right anterior temporal lobectomy, matching the findings in the differential tractogram that
727 shows the affected pathways around the surgical location. The false findings in the normal subject can


728 be differentiated by their less significant decrease of anisotropy and their location at the anterior frontal
729 region, which is known to be more susceptible to phase distortion artifact.

730

a



b



731

732 **Fig. 7**

733 Performance differences in differential tractography due to different b-values. (a) Diffusion-weighted
734 images of a patient at b-values of 0, 3000, and 7000 s/mm². Signals at high b-values are sensitive to
735 restricted diffusion but have a lower signal-to-noise ratio. Thus most clinical scans only acquire b-value
736 lower than 3000 s/mm². (b) Differential tractography using reduced b-values between 0 and 3,000 s/mm²
737 shows 54% fewer findings than those from the full dataset using b-values between 0 and 7,000 s/mm².
738 Although the reduced b-value dataset also shows a grossly similar result, its FDR is substantially higher
739 (FDR=0.32) and thus not as reliable as the full dataset that includes high b-value data. This indicates the
740 important role of high b-value acquisition in detecting early neuronal injury.

741

Table 1: Patient Demographics and Major Symptoms

	diagnosis	age	sex	MRI scans	Major symptoms
#1	multiple sclerosis	44	F	onset of symptom and 6-month follow-up	acute onset of left ocular pain, pain with eye movements, blurring vision of the left eye (20/400), loss of visual field in all quadrants.
#2	multiple sclerosis	24	F	onset of symptom and 6-month follow-up	acute onset of left ocular pain, pain with eye movements, blurring vision of the right eye (20/125), superior altitudinal visual field defect.
#3	Huntington disease	60	M	two scans at 5 months apart during the manifest stage	body bradykinesia on both sides UHDRS motor: 45→49 (worsening)
#4	Huntington disease	55	F	two scans at 5 months apart during the manifest stage	dystonia of left upper extremity, dragging right foot with ambulation, dystonia of the right leg UHDRS motor: 53→64 (worsening)
#5	ALS	48	M	baseline scan acquired 30 months after onset follow-up scan acquired one year after.	left-hand weakness with fasciculations ALSFRS-R: 45→32 (worsening)
#6	epilepsy	51	M	before anterior temporal lobectomy and one-year follow-up after surgery	

ALS: amyotrophic lateral sclerosis, **UHDRS:** Unified Huntington's Disease Rating Scale, **ALSFRS-R:** Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised

742

	diagnosis	change threshold	length threshold	number of findings	false-positive findings*	FDR
#1	multiple sclerosis	30%	40 mm	13,947	177	≤0.0126
#2	multiple sclerosis	30%	40 mm	2,799	0	<0.0001
#3	Huntington disease	30%	40 mm	85,243	3,571	≤0.0419
#4	Huntington disease	30%	40 mm	64,272	0	<0.0001
#5	ALS	15%†	40 mm	12,222	2,548	≤0.2085
#6	epilepsy post-op	30%	40 mm	15,959	0	<0.0001
	normal control	30%	40 mm	74		

* estimated by the number of tracks with increased anisotropic diffusion

†30% yields no findings

743

744

Table 3: Differential Tractography Using Reduced Datasets (b = 0 ~ 3000 s/mm²)

	diagnosis	number of findings and its change(%)†	false-positive findings*	FDR
#1	multiple sclerosis	6,454 (-53.72%)	2,071	≤0.3208
#2	multiple sclerosis	507 (-81.89%)	0	<0.0001
#3	Huntington disease	2,437 (-97.14%)	865	≤0.3549
#4	Huntington disease	39,903 (-37.92%)	0	<0.0001
#5	ALS	2,211 (-81.91%)	473	≤0.2139
#6	epilepsy post-op	7464 (-53.23%)	360	≤0.0482
	normal control	636 (+759.46%)		

*estimated by the number of tracks with increased anisotropic diffusion

†the change is calculated by $(a-b)/b$, a : current value b : previous value

745

746

747 **Supplementary Materials**

748 **Patient's medical history during the scan interval**

749 *MS patients*

750 Patient #1 was a 44-year-old female with acute onset of left ocular pain and pain with eye movements.
751 She experienced a gradual decline in her visual acuity, and initial visual examination showed normal
752 acuity in the right eye and decreased acuity in the left eye (20/70), which worsen to 20/400 in one week.
753 She had a dense superior visual field defect in both superior quadrants that continued to worsen over a
754 few days with gradual loss of the inferior visual fields. She was treated with IV steroids, and after the
755 treatment, the ocular pain, pain with eye movement, and the visual field were improved. After 6 months
756 of her initial presentation, her visual acuity returned to 20/20 both eyes and the visual fields were normal

757 Patient #2 was a 23-year-old female with the blurring of vision of the right eye, associated with ocular
758 pain and pain with extraocular movements. Initial evaluation by ophthalmology noted visual acuity of
759 20/40 with enlargement of the blind spot on the Humphrey visual field. Within a week her symptoms
760 progressed to a visual acuity of 20/125, decrease in the color perception. and a superior altitudinal visual
761 field defect. She was treated with intravenous methylprednisolone according to the optic neuritis
762 treatment trial. Her symptoms recovered within 10 days to visual acuity of 20/25 and normal color
763 saturation.

764 *HD patients*

765 Patient #3 was a 60-year-old male. The age of onset was 56, and the CAG repeats were 42. During the
766 scan interval, the UHDRS motor total was increased from 45 to 49, with most prominent symptoms of
767 body bradykinesia on both sides.

768 Patient #4 was a 55-year-old female. The age of onset was 48, and the CAG repeats were 43. During
769 the scan interval, the UHDRS motor total was increased from 53 to 64, with symptoms of dystonic
770 contractures of the left upper extremity, dragging right foot with ambulation, and dystonia in the legs
771 more obvious with gait (mostly on the right side), moderate bradykinesia with the finger taps (mostly on
772 the left side).

773 *ALS patient*

774 Patient #5 was a 48-year-old male ALS patient (laboratory-supported probable ALS diagnosis) with
775 upper extremity limb onset and predominant lower motor neuron involvement. His symptoms started
776 about 30 months before the baseline scan with widespread fasciculations and left-hand weakness.
777 There were subtle upper motor neuron signs in cervical segments. He developed lower extremity
778 weakness 2 years after onset but never developed lower extremity upper motor neuron signs at the time
779 of death that occurred 5 years after the onset of symptoms. He had no family history of neurological
780 disease. The patient's ALSFRS-R score decreased from 45 to 32 during the MRI scan interval (1 year
781 apart).

782 *Epilepsy patient*

783 Patient #6 was a 51-year-old male with medically intractable epilepsy since the age of 17. His seizure
784 frequency was weekly, and intracranial monitoring demonstrated that his seizure onset zone included
785 the right mesial and neocortical temporal lobe. He underwent a standard right anterior temporal
786 lobectomy. MRI scans were obtained before the surgery and one year after the surgery.

